



Development and Validation of a New Reverse Phase Liquid Chromatographic Method for the Assay of Tilorone

Yenda Manishankar* and Mukthinuthalapati Mathrusri Annapurna

Department of Pharmaceutical Analysis and Quality Assurance, GITAM Institute of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, India

*Corresponding Author: Yenda Manishankar, Department of Pharmaceutical Analysis and Quality Assurance, GITAM Institute of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, India.

Received: May 22, 2021

Published: July 21, 2021

© All rights are reserved by **Yenda**

Manishankar and Mukthinuthalapati Mathrusri Annapurna.

Abstract

A new RP-HPLC method has been proposed for the assay of Tilorone in API and its tablet dosage forms. Tilorone is an anti-viral immune stimulating medication. It can be used for the treatment of viral hepatitis A, B, C, urogenital tract and respiratory infections. It stimulates the formation of α -, β -, γ -interferons and produces interferon intestinal epithelial cells, neutrophils, T-lymphocytes and hepatocytes in the body. A mobile phase composition consisting of tetra butyl ammonium hydrogen sulphate and acetonitrile was chosen for the chromatographic study on isocratic mode. C8 Agilent column has been used for the chromatographic elution of Tilorone and the HPLC system was monitored at 264 nm with flow rate 0.5 mL/min. Tilorone has shown linearity over the concentration range 0.05-40 $\mu\text{g/mL}$ and the regression equation was $y = 428331x + 24602$ with correlation coefficient 0.9999. The LOD and LOQ are found to be 0.0138 and 0.0429 $\mu\text{g/mL}$ respectively. The method was validated as per ICH guidelines. The proposed RP-HPLC method was found to be precise, accurate, and robust for the quantification of Tilorone in pharmaceutical dosage forms.

Keywords: RP-HPLC; Tilorone; Acetonitrile; ICH Guidelines

Introduction

Tilorone (CAS 0027591-97) is an effective anti-viral agent against influenza viruses, herpesviruses, hepato viruses etc. Tilorone hydrochloride (Figure 1) is a synthetic orally active interferon inducer which has anti-cancer as well as anti-inflammatory activities. The antiviral action of Tilorone is associated with the inhibition of translation of virus-specific proteins followed by the suppression of virus replication. Tilorone is a fluoren-9-ones derivative and it is an alpha 7-nicotinic acetyl choline receptor agonist. It has a molecular formula $\text{C}_{24}\text{H}_{34}\text{Cl}_2\text{N}_2\text{O}_3 \cdot 2\text{HCl}$ and molecular weight 483.47. Very few analytical methods were so far developed in the literature HPLC/MS/MS methods were developed by Zhang, *et al.* [2] and Xianhua, *et al.* [3] for the simultaneous quantification of Tilonoxim and Tilorone in human urine in presence of

an internal standard, Metoprolol and also in human blood respectively. Tilorone is an active major metabolite of Tilonoxim. One spectrophotometric [4] method and one RP-UFLC [5] method were reported in the literature for the assay of Tilorone in pharmaceutical dosage forms. At present the authors proposed a new reverse phase liquid chromatographic method (RP-HPLC) for the quantification of Tilorone in tablets and the method were validated as per ICH guidelines [6].

Materials and Methods

Instrumentation and Chemicals

Acetonitrile (HPLC grade) and tetra butyl ammonium hydrogen sulphate (TBHS) were procured from Merck (India). Shimadzu Model HPLC system with C8 Agilent column and photodiode array

detector were used for the chromatographic analysis. Tilorone was supplied by HONOUR Labs Limited (Hyderabad, India) as gift sample. Tilorone is available with brand names AMIXIN and LAVOMAX (Label claim: 60 mg) as film coated tablets.




Figure 1: Chemical structure of Tilorone.

Preparation of tetra butyl ammonium hydrogen sulphate solution (pH 3.5)

The molecular weight of tetra butyl ammonium hydrogen sulphate is 339.5 grams/mole and it is an ion pairing reagent. 10 mM solution of tetra butyl ammonium hydrogen sulphate was prepared by dissolving accurately 3.395 grams in HPLC grade water in a 1000 ml volumetric flask and the solution was sonicated, filtered through a membrane filter and then used as mobile phase.

Preparation of Tilorone stock (1000 µg/mL) solution

25 mg of Tilorone was accurately weighed and dissolved in a 25 mL volumetric flask and made up to the volume with acetonitrile (HPLC grade) to obtain 1000 µg/mL. This stock solution was diluted as per the requirement with the diluent and filtered through membrane filter before use. The diluent used was TBHS: Acetonitrile (50:50, v/v).

Method validation [6]

Linearity study

A series of solutions (0.05- 40 µg/mL) were prepared from the stock solution and diluted with mobile phase. 20 µL of each of these solutions were injected in to the HPLC system and the peak area of each chromatogram was noted. A calibration curve was drawn by plotting the concentration on the x-axis and the corresponding mean peak area values on the y-axis.

Precision study

Precision study was performed on the same day with three different concentrations and on different days using three different

concentrations which are called as Intraday and Inter-day precision studies respectively. Three different concentrations 5, 10 and 20 µg/mL of Tilorone solutions were prepared for intraday and interday precision studies and each solution was injected three times (n=3) on the same day and on three consecutive days and the average peak area was calculated from the individual chromatograms obtained.

Accuracy study

The accuracy study was performed using the standard addition method. In this study the recovery values and the % RSD values were calculated. In this method 50%, 100% and 150% of the pure drug (API) solutions were added to a fixed concentration of the extracted formulation solution and 20 µL of each of these resultant solutions were injected (n = 3) in to the HPLC system and the peak area of each chromatogram was noted. The mean peak area was calculated and there by the percentage recovery was calculated using the linear regression equation obtained in the linearity study.

Robustness study

Robustness is one of the important validated parameters and in this study small changes such as flow rate (± 0.1 mL/min), mobile phase ratio ($\pm 2\%$), pH and detection wave length (259 nm and 269 nm) were incorporated in the optimized method and 20 µL of 10 µg/ml of solution was injected (n = 3) in to the HPLC system after attaining the base line with the incorporated changes one by one and the peak area of each chromatogram obtained was noted. The mean peak area of the chromatograms obtained from each incorporated change was calculated and there by the percentage recovery was also calculated using the linear regression equation obtained in the linearity study.

Assay of commercial formulation (Tablets)

20 tablets of two different brands of Tilorone available in pharmacy store were purchased, weighed powdered. Powder equivalent to 25 mg Tilorone was weighed accurately and extracted with HPLC grade acetonitrile. The extracted solution was further diluted with the mobile phase, sonicated for half an hour and filtered through 0.45 mm membrane filter before injecting in to the HPLC system to prevent the particulate matter if any. 20 µL of these solutions were injected (n = 3) in to the HPLC system and the mean peak area was noted from the respective chromatograms. The percentage of purity was calculated by substituting the mean peak area value in the linear regression equation.

Results and Discussion

A new reverse phase liquid chromatographic method has been developed for the determination of Tilorone in pharmaceutical

dosage forms using Shimadzu Model HPLC system with C8 Agilent column and photo diode array detector. The previously published analytical methods were compared with the present proposed method in table 1. Mobile phase mixture consisting of tetra butyl ammonium hydrogen sulphate and acetonitrile was selected for the

chromatographic study. Tetra butyl ammonium hydrogen sulphate is an ion pairing reagent. The run time was 10 minutes and the detection wavelength was at 264 nm. The chromatographic study was performed isocratic mode with a flow rate of 0.5 mL/min.

Method	Mobile phase (% v/v)	Linearity ($\mu\text{g/mL}$)	Comments	Ref
HPLC-MS/MS Metoprolol (Internal standard)	Methanol: 15 mM Ammonium bicarbonate (pH 10.5)	0.001-0.1	Human urine Gradient mode	[2]
HPLC-MS/MS	Methanol: 15 mM Ammonium bicarbonate (pH 10.5)	0.001-0.1	Human Blood Gradient mode	[3]
Spectrophotometry	Sodium acetate buffer (pH 4) Borate buffer (pH 9.0) Phosphate buffer (pH 2.0) Phosphate buffer (pH 5.0)	0.4-14	Good linearity	[4]
RP-UFLC	0.1% TEA: Acetonitrile (pH 3.2 adjusted with OPA)/(40:60)	0.1-20	Stability indicating (PDA)	[5]
RP-HPLC	Tetra butyl ammonium hydrogen sulphate: Acetonitrile (61: 39)	0.05-40	Ion pairing agent	Present method

Table 1: Comparison of previously published methods with the present method.

Method development and optimization

Initially a mobile phase consisting of tetra butyl ammonium hydrogen sulphate and methanol (20: 80) was chosen with flow rate 1.0 ml/min for the chromatographic study and Tilorone was eluted at 1.307 mins. Therefore methanol in the mobile phase was replaced with acetonitrile and the ratio was maintained at 50: 50 with flow rate 0.8 ml/min. Tilorone was eluted at 1.466 min with theoretical plates less than 2000. Later the flow rate was decreased

to 0.5 ml/min and the retention time of Tilorone was shifted to 1.917 min with theoretical plates more than 2000. To shift the retention time the organic phase was decreased and finally Tilorone was eluted at 2.338 mins and the system suitability parameters were satisfied. The method was optimized with mobile phase, TBHS: Acetonitrile (61:39, v/v) with flow rate 0.5 ml/min and the detection was carried out at 264 nm. The trials runs obtained during the optimization process were shown in Figure 2 and the summary of details was given in table 2.

Trial	Mobile phase (v/v)	Flow rate (mL/min)	Rt (min)	Theoretical plates	Tailing factor	Comment
1	TBHS: Methanol (20:80)	1.0	1.307	1631.166	3.424	Tailing factor >2 Theoretical plates <2000 Rt less than 2 min
2	TBHS: Acetonitrile (50:50)	0.8	1.466	1934.812	1.639	Theoretical plates <2000 Rt less than 2 min
3	TBHS: Acetonitrile (50:50)	0.5	1.917	2277.787	1.591	Rt less than 2 min
4	TBHS: Acetonitrile (61:39)	0.5	2.338	2320.445	1.212	Method optimized

Table 2: Method optimization.




Figure 2: Chromatograms obtained during the method optimization of Tilorone (10 µg/ml).

Method validation

The proposed method was validated by linearity, precision, accuracy, robustness as per the ICH guidelines for the determination of Tilorone. Tilorone has shown linearity over the concentration range 0.05-40 µg/mL (Table 3) and the regression equation was $y = 428331x + 24602$ with correlation coefficient 0.9999. The LOD and

LOQ are found to be 0.0138 and 0.0429 µg/mL respectively. The calibration curve was shown in figure 3. The representative chromatograms obtained for the placebo and that of Tilorone standard (API) were shown in Figure 4. The system suitability parameters are within the acceptable criteria.

Conc. (µg/mL)	*Mean peak area	%RSD	Theoretical plates	Tailing factor
0.05	24337	0.39	2498.226	0.979
0.1	47923	0.23	2564.332	0.867
0.5	232921	0.48	2778.329	1.221
1	454256	0.32	2337.005	1.463
2	873387	0.41	2464.754	1.301
5	2231224	0.29	2332.290	1.495
10	4403233	0.34	2302.556	1.374
20	8455549	0.31	2569.534	1.290
30	12943257	0.49	2645.189	1.392
40	17142681	0.52	2561.267	1.269

Table 3: Linearity study.

*Mean of three replicates.




Figure 3: Calibration curve of Tilorone.

Intraday and inter-day precision were studied and the % RSD was found to be 0.21-0.33 and 0.38-0.59 respectively (<2.0 %) showing that the method is precise (Table 4 and Table 5). The % RSD in accuracy was found to be 0.73-0.91 (<2.0 %) with a recov-

ery of 99.33-99.47 % showing that the method is accurate (Table 6). In robustness study the % RSD was found to be 0.27-1.23 which is less than 2.0 indicating that the method is robust (Table 7).

Conc. (µg/mL)	Peak area (AUC)	Statistical Analysis
		*Mean peak area ± SD (% RSD)
5	2231321	2231306 ± 7363.31 (0.33)
5	2231296	
5	2231301	
10	4423215	4424190 ± 9290.80 (0.21)
10	4424136	
10	4425219	
20	8456024	8455876.67 ± 2830.87 (0.27)
20	8455933	
20	8455673	

Table 4: Intraday precision study.

*Mean of three replicates.

Conc. (µg/mL)	*Mean peak area			*Mean ± SD(% RSD)
	Day 1	Day 2	Day 3	
5	2302562	2283012	2292261	2292611.67 ± 9628.97 (0.42)
10	4510022	4511214	4510354	4510530 ± 26612.13 (0.59)
20	8362533	8359847	8358475	8360285 ± 31769.08 (0.38)

Table 5: Interday precision study.

*Mean of three replicates.

Conc (µg/mL)			*Average conc. (% RSD)	% Recovery
Formulation	Pure drug	Total		
6	3	9	8.94 (0.89)	99.33
6	3	9		
6	3	9		
6	6	12	11.93 (0.73)	99.41
6	6	12		
6	6	12		
6	9	15	14.92 (0.91)	99.47
6	9	15		
6	9	15		

Table 6: Accuracy study.

*Mean of three replicates.

Parameter	Condition	*Mean peak area ± SD (% RSD)
Flow rate (± 0.1 ml/min)	0.4	4415984 ± 44601.44 (1.01)
	0.5	
	0.6	
Detection wave-length (± 2 nm)	259	4404521 ± 11892.21 (0.27)
	264	
	269	
Mobile phase composition	56: 44	4405269 ± 25991.09 (0.59)
	61:39	
	TBHS: Acetonitrile (± 2 %, v/v)	
pH (± 0.1 unit)	3.4	4410256 ± 54246.15 (1.23)
	3.5	
	3.6	

Table 7: Robustness study.

Assay of tilorone tablets

The analytical method i.e. RP-HPLC method developed for the determination of Tilorone was validated and it was applied for the assay of marketed formulations. The percentage of recovery was found to be 99.82- 99.88 (Table 8). The typical chromatogram obtained for the marketed formulations were shown in figure 4.

Formulation	Label claim (mg)	*Amount found (mg)	*Recovery (%)
Brand I	60	59.93	99.88
Brand II	60	59.89	99.82

Table 8: Assay of Tilorone.

*Mean of three replicates.




Figure 4: Representative chromatograms of Tilorone.

Conclusion

The proposed RP-HPLC method was validated as per ICH guidelines and can be used for the determination of Tilorone in pharmaceutical dosage forms. This method is also useful for performing the pharmacokinetic studies and also for the assay of Tilorone in biological samples.

Acknowledgement

The authors are grateful to HONOUR Labs Limited (Hyderabad, India) for supplying Tilorone as gift sample. There is no conflict of interest.

Bibliography

1. Stringfellow D and Glasgow L. "Tilorone hydrochloride: An oral interferon-inducing agent". *Antimicrobial Agents Chemotherapy* 2.2 (1972): 73-78.
2. Zhang X., et al. "Simultaneous quantification of Tilonoxim and Tilorone in human urine by liquid chromatography-tandem mass spectrometry". *Journal of Chromatography B* 875.2 (2008): 349-357.
3. Xianhua Zhanga., et al. "Performance of Tilonoxim and Tilorone determination in human blood by HPLC-MS/MS: Method validation, uncertainty assessment and its application to a pharmacokinetic study". *Journal of Chromatography B* 878. 3-4 (2010): 492-496.

4. Mathrusri Annapurna M and Sri Valli D. "Derivative spectrophotometric methods for the determination of Tilorone - An Anti-retroviral Drug". *Asian Journal of Pharmaceutics* 12.1 (2018): S 288-S 295.
5. Hima Bindu G., et al. "New stability indicating ultrafast liquid chromatographic method for the determination of Tilorone in tablets". *Research Journal of Pharmacy and Technology* 11.9 (2018): 3950-3956.
6. ICH validation of analytical procedures: text and methodology Q2 (R1), International Conference on Harmonization (2005).

Volume 5 Issue 8 August 2021

© All rights are reserved by Yenda Manishankar and Mukthinuthalapati Mathrusri Annapurna.